Friday 16 October 2026 Export ADCT’s income statement to Excel — free account

ADC Therapeutics SA

ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.

1.41 0.08 −5.37%

Follow ADCT

Alert me

Market cap: $190.2M
P/E: 0.0×
Fwd P/E: −1.2×
Dividend yield: —
F-score: 5/9
Altman Z: −6.67
Beneish M: −2.09
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 19.64

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	1	—	—	—	—	—	—	—

Insider Ownership 36.11%

Capital & Financial Ratios $m

Market Cap 190.23

Revenue 79.58

Net Income (96.91)

Free Cash Flow (101.64)

Net Debt (102.49)

Current Ratio 3.03

Debt/Equity (0.51)

P/E ratio 0.00

Fwd P/E (1.21)

P/S ratio 2.75

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 32.81%

Next Y EPS Growth 10.30%

Next Y revenue growth (0.99%)

Next 5Y EPS Growth 32.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 42.39%

10-year low 10-year high

EV/Sales against its own 10 years 34.61%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	279	251	261	219
Receivables	25	20	29	28
Inventory	16	2	4	5
Other	6	9	6	4
	336	291	306	262

	2023	2024	2025	Q'26
Payables	16	18	9	13
ST’ Debt	—	—	3	6
Other	—	—	—	—
	68	80	70	86

Compound Annual Growth %

	10y	5y	3y
Sales	—	103.35%	(27.09%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	21	19	—	—	—
’25	23	19	16	23	81
’24	18	17	18	17	71
’23	19	19	14	17	70
’22	46	17	76	70	210
’21	—	4	13	17	34
’19	—	2	—	—	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(30)	(12)	—	—	—
’25	(56)	(24)	(30)	(31)	(141)
’24	(44)	(33)	(25)	(22)	(124)
’23	(15)	(35)	(37)	(32)	(119)
’22	(34)	(53)	2	(54)	(138)
’21	(55)	(58)	(59)	(62)	(233)
’20	(32)	(41)	(44)	(52)	(169)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(30)	(12)	—	—	—
’25	(57)	(24)	(30)	(30)	(141)
’24	(45)	(33)	(25)	(22)	(125)
’23	(16)	(36)	(37)	(32)	(122)
’22	(35)	(54)	2	(54)	(141)
’21	(56)	(61)	(61)	(62)	(240)
’20	(33)	(41)	(46)	(52)	(172)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.21)	(0.11)	—	—	—
’25	(0.36)	(0.50)	(0.30)	(0.04)	(1.12)
’24	(0.56)	(0.38)	(0.42)	(0.29)	(1.62)
’23	(0.74)	(0.58)	(0.58)	(1.03)	(2.94)
’22	(0.22)	(0.84)	(0.65)	(0.30)	(1.99)
’21	(0.67)	(0.95)	(0.93)	(0.45)	(3.00)
’20	(0.85)	(2.01)	(0.29)	(0.73)	(3.77)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	25.11	18.33	2.69	0.36	1.45	1.05	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	56.59	34.48	20.67	5.75	6.04	4.80
People
People	Employees	—	—	—	179	208	312	317	274	265	193
	Revenue/emp, $m	—	0.00	0.00	0.01	0.00	0.11	0.66	0.25	0.27	0.42
Income, $m
Income, $m	Revenue	—	2	1	2	—	34	210	70	71	81
	Gross margin, %	—	0.00	100.00	100.00	0.00	95.89	98.43	96.36	91.60	92.87
	EBT	—	(90)	(123)	(116)	(246)	(252)	(147)	(195)	(156)	(142)
	EBT margin, %	—	(4,981.36)	(10,778.25)	(4,953.08)	0.00	(741.53)	(69.94)	(280.94)	(220.42)	(174.06)
	Net income	—	0	(123)	(116)	(246)	(230)	(157)	(240)	(158)	(143)
	Depreciation	—	0	1	2	2	3	2	3	3	2
Per share, $
Per share, $	Revenue	—	581.61	0.02	0.05	0.00	0.44	2.69	0.85	0.73	0.64
	Earnings	—	(28,664.00)	(2.64)	(2.36)	(3.77)	(3.00)	(1.99)	(2.94)	(1.62)	(1.12)
	Cash flow	—	(24,175.81)	(2.60)	(2.47)	(2.58)	(3.04)	(1.77)	(1.45)	(1.27)	(1.11)
	Capex	—	0.00	(0.05)	(0.04)	(0.04)	(0.08)	(0.03)	(0.04)	(0.01)	0.00
	Free cash flow	—	(24,175.81)	(2.66)	(2.51)	(2.62)	(3.12)	(1.80)	(1.49)	(1.28)	(1.11)
	Book value	—	80,376.13	2.71	2.26	5.13	2.16	1.02	(1.81)	(2.09)	(1.46)
	Shares, m	—	0	47	49	65	77	78	82	97	127
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.00	0.00	0.00	—	43.21	1.34	1.99	2.73	5.51
	P/B	—	13.75	13.75	13.75	—	9.33	3.53	0.00	0.00	0.00
	EV/Sales	—	0.00	0.00	0.00	—	33.88	0.36	(0.19)	0.99	3.72
	EV/FCF	—	(9.19)	(9.19)	(9.19)	—	(5.06)	(0.54)	0.11	(0.56)	(2.15)
Cash, $m
Cash, $m	Operating cash flow	—	(75)	(121)	(122)	(169)	(233)	(138)	(119)	(124)	(141)
	Capex	—	(3)	(2)	(2)	(3)	(6)	(2)	(3)	(1)	0
	Free cash flow	—	(75)	(124)	(124)	(172)	(240)	(141)	(122)	(125)	(141)
Balance, $m
Balance, $m	Working capital	—	245	120	103	410	451	353	269	211	236
	Total debt	—	—	—	5	112	132	122	113	114	115
	Net debt	—	(263)	(139)	(111)	(328)	(335)	(204)	(166)	(137)	(146)
	Shareholders’ equity	—	249	126	111	336	166	79	(148)	(203)	(186)
Returns, %
Returns, %	ROA	—	(42.54)	(163.52)	(80.82)	(75.62)	(40.65)	(28.34)	(56.77)	(46.65)	(44.22)
	ROIC	—	0.00	0.00	(11,733.39)	(1,729.42)	0.00	0.00	0.00	0.00	0.00
	ROE	—	(47.87)	(65.58)	(98.13)	(110.28)	(91.72)	(127.99)	697.85	89.97	73.43

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LXEO Lexeo Therapeutics, Inc.	$226.6M	— (loss-making)	— (loss-making)	—	n/m	+35.58% (above 0%: growing)	0.00%	0.00%	Compare
KROS Keros Therapeutics, Inc.	$220.1M	— (loss-making)	— (loss-making)	−99.83% (below 0%: shrinking)	n/m	+32.19% (above 0%: growing)	100.00%	0.00%	Compare
CAMP CAMP4 Therapeutics Corporation	$216.5M	— (loss-making)	— (loss-making)	+18.84% (above 0%: growing)	n/m	−23.90% (below 0%: shrinking)	100.00%	(752.11%)	Compare
PYXS Pyxis Oncology, Inc.	$215.3M	— (loss-making)	— (loss-making)	—	n/m	−5.46% (below 0%: shrinking)	100.00%	0.00%	Compare
EVMN Evommune Inc.	$215.2M	— (loss-making)	— (loss-making)	—	n/m	+21.78% (above 0%: growing)	100.00%	0.00%	Compare
MGNX MacroGenics, Inc.	$214.7M	— (loss-making)	— (loss-making)	+377.97% (above 0%: growing)	n/m	+12.88% (above 0%: growing)	100.00%	(42.19%)	Compare
ZNTL Zentalis Pharmaceuticals, Inc.	$212.1M	— (loss-making)	— (loss-making)	—	n/m	−9.06% (below 0%: shrinking)	100.00%	0.00%	Compare
LRMR Larimar Therapeutics, Inc.	$206.7M	— (loss-making)	—	—	n/m	−127.63% (below 0%: shrinking)	0.00%	0.00%	Compare
ADCT ADC Therapeutics SA	$190.2M	— (loss-making)	— (loss-making)	+2.17% (above 0%: growing)	n/m	+50.98% (above 0%: growing)	87.80%	(132.03%)
Median of peers	$215.2M	—	—	+18.84%	—	+3.71%	100.00%	0.00%

All 614 Biotechnology stocks →

ADC Therapeutics SA (ADCT) key facts

Strength: ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024.
ADC Therapeutics SA (ADCT) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, ADCT traded at $1.41, a market capitalization of $190.2 million.
Return on equity was 73.4% and debt-to-equity -0.51.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −6.67 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.